A Propensity-Matched Study of the Comparative Effectiveness of Angiotensin Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors in Heart Failure Patients Age ?5 Years

详细信息    查看全文

• 作者：Yan  ; Zhang MS ; MSPH^a ; Gregg C.  ; Fonarow MD^b ; Paul W.  ; Sanders MD^a ;   ; ^c ; Firoozeh  ; Farahmand MD ; PhD^d ; Richard M.  ; Allman MD^a ;   ; ^c ; Inmaculada B.  ; Aban PhD^a ; Thomas E.  ; Love PhD^e ; Raynald  ; Levesque MSc^f ; Meredith L.  ; Kilgore PhD^a ; Ali  ; Ahmed MD ; MPH^a ;   ; ^c ;   ; ^{aahmed@uab.edu}
• 刊名：The American Journal of Cardiology
• 出版年：2011
• 出版时间：15 November 2011
• 年：2011
• 卷：108
• 期：10
• 页码：1443-1448
• 全文大小：881 K

文摘

The comparative effectiveness of angiotensin-converting enzyme (ACE) inhibitors versus angiotensin II type 1 receptor blockers (ARBs) in real-world older heart failure (HF) patients remains unclear. Of the 8,049 hospitalized HF patients aged ?5 years discharged alive from 106 Alabama hospitals, 4,044 received discharge prescriptions of either ACE inhibitors (n = 3,383) or ARBs (n = 661). Propensity scores for ARB use, calculated for each of 4,044 patients, were used to match 655 (99 % of 661) patients receiving ARBs with 661 patients receiving ACE inhibitors. The assembled cohort of 655 pairs of patients was well balanced on 56 baseline characteristics. During >8 years of follow-up, all-cause mortality occurred in 63 % and 68 % of matched patients receiving ARBs and ACE inhibitors, respectively (hazard ratio [HR] associated with ARB use 0.86, 95 % confidence interval [CI] 0.75 to 0.99, p = 0.031). Among the 956 matched patients with data on the left ventricular ejection fraction (LVEF), the association between ARB (vs ACE inhibitor) use was significant in only 419 patients with LVEFs ?5 % (HR 0.65, 95 % CI 0.51 to 0.84, p = 0.001) but not in the 537 patients with LVEFs <45 % (HR 1.00, 95 % CI 0.81 to 1.23, p = 0.999; p for interaction = 0.012). HRs for HF hospitalization associated with ARB use were 0.99 (95 % CI 0.86 to 1.14, p = 0.876) overall, 0.80 (95 % CI 0.63 to 1.03, p = 0.080) in those with LVEFs ?5 % , and 1.14 (95 % CI 0.91 to 1.43, p = 0.246) in those with LVEFs <45 % (p for interaction = 0.060). In conclusion, in older HF patients with preserved LVEFs, discharge prescriptions of ARBs (vs ACE inhibitors) were associated with lower mortality and a trend toward lower HF hospitalization, findings that need replication in other HF populations.